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Running head: Magnesium and memantine in primary head pain 
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Abstract 
Experimental and clinical studies suggest that the low-affinity N-methyl-D-aspartate (NMDA) 
receptor open-channel blockers Mg
2+
 and memantine are effective in reducing trigeminal 
nociceptive activation. The aim of the present study was to investigate the apparent 
effectiveness of these channel blockers using a model of trigeminal activation in vivo. Rats 
were anesthetized before electrically stimulating the dura mater adjacent the middle 
meningeal artery. Neurons responding to stimulation were recorded extracellularly using 
electrophysiological methods while L-glutamate or NMDA and Mg
2+
, memantine, or sodium 
controls were applied locally using microiontophoresis. Microiontophoretic application of 
Mg
2+
 or memantine into the trigeminocervical complex inhibited mechanically and 
electrically-stimulated craniovascular afferent, L-glutamate, or NMDA-evoked neuronal 
activity at the second order trigeminal synapse of craniovascular afferents. By contrast, 
intravenous administration of MgSO4 (100 mg/kg) or memantine (10 mg/kg) did not 
significantly affect electrically-stimulated afferent-evoked activity within the 
trigeminocervical complex. The Mg
2+
 and memantine concentrations achieved after systemic 
administration may not effectively inhibit activation of the trigeminocervical complex, 
perhaps providing an explanation for the relatively poor efficacy of these NMDA receptor 
open-channel blockers for headache treatment in clinical studies. Nevertheless, the present 
results suggest blocking of NMDA-receptor open channels inhibits nociceptive activation of 
the trigeminocervical complex. Further exploration of such channel blockers as a therapeutic 
strategy for primary head pain is warranted. 
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Introduction 
Migraine is the most common cause of disability globally (GBD 2016 Disease and Injury 
Incidence and Prevalence Collaborators, 2017). It is a brain disorder (Akerman et al., 2011; 
Goadsby et al., 2017) characterized by impaired habituation to sensory information 
(Ambrosini et al., 2003). Clinical and experimental evidence suggests that glutamate 
receptors are involved in the pathophysiology of migraine (Nicolodi & Sicutieri, 1995; 
Ramadan et al., 2003; Vikelis & Mitsikostas, 2007), which thus offers potential targets for 
therapeutic approaches to migraine and primary head pain (Andreou & Goadsby, 2009). 
The NMDA receptor is widely distributed in the central nervous system. It generally 
comprises a tetramer, formed by two GluN1 subunits, which are present in all functional 
NMDA receptors, and two GluN2 subunits of various types A–D to form a channel pore. 
GluN1 subunits express a glycine-binding site and GluN2 subunits express a glutamate-
binding site (Kew & Kemp, 2005; Parsons et al., 2007). NMDA-receptor activation requires 
simultaneous binding of glycine and glutamate, together with removal of the endogenous 
channel-pore blocker Mg
2+
 in a voltage-dependent manner (Kleckner & Dingledine, 1988). 
The NMDA-receptor channel is normally relatively permeable to Ca
2+
, and at resting 
potentials Mg
2+
, memantine, or ketamine, can block the channel, impeding Ca
2+
 influx 
(Alexander et al., 2011). During local depolarization of neurons, the NMDA receptor channel 
changes conformation allowing Mg
2+
, to leave the channel pore, and Ca
2+
 influx. Memantine 
and ketamine also dissociate from the channel pore in a voltage-dependent manner, but 
require a greater change in voltage to do so (Parsons et al., 1999). 
A role for Mg
2+
 deficiency in headache was proposed in the 1980s (Altura, 1985). Clinical 
studies have found that Mg
2+
 levels are reduced in the saliva, serum (Sarchielli et al., 1992), 
and cerebrospinal fluid (Jain et al., 1985) of migraineurs, during and between migraine 
attacks. These findings are further supported by a study using nuclear magnetic resonance 
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spectroscopy that found low levels of Mg
2+
 in the brains of migraineurs (Ramadan et al., 
1989). At least three other studies have found reduced Mg
2+
 levels in the serum of 
migraineurs (Mauskop et al., 1995; Soriani et al., 1995; Mauskop et al., 1996). Clinical trials 
of migraine treatment with magnesium showed promising results initially (Facchinetti et al., 
1991; Mauskop et al., 1995). However, randomized, double-blind, placebo-controlled trials 
have mostly failed to realize this initial promise (Peikert et al., 1996; Pfaffenrath et al., 1996; 
Bigal et al., 2002). 
The potential efficacy of memantine for the treatment of migraine has been tested clinically 
including in open-label pilot studies, a case series, and most recently a randomized placebo-
controlled trial, which taken together suggest effectiveness (Cammarata & Krusz, 2005; Kew 
& Kemp, 2005; Charles et al., 2007; Bigal et al., 2008; Spengos et al., 2008; Noruzzadeh et 
al., 2016). Memantine is generally well tolerated because of its relatively fast channel off-rate 
and partial untrapping (Parsons et al., 2007). It does not substantially accumulate in the 
channel to interfere with subsequent normal synaptic transmission (Lipton, 2007). By 
contrast, other NMDA receptor antagonists such as ketamine, with its higher affinity for the 
channel, while perhaps effective in migraine treatment (Nicolodi & Sicutieri, 1995; Kaube et 
al., 2000; Afridi et al., 2013) has unacceptable dose-limiting clinical side effects (Hocking & 
Cousins, 2003; Visser & Schug, 2006; Chizh, 2007; Blonk et al., 2010). 
In experimental studies, both Mg
2+
 and memantine inhibited cortical spreading depression 
(CSD), considered a pathophysiological analog of migraine aura (Mody et al., 1987; van der 
Hel et al., 1998; Peeters et al., 2007). Consistent with this inhibition, Mg
2+
 deficiency 
increases the sensitivity of NMDA receptors to glutamate-induced CSD (Van Harreveld & 
Fifkova, 1973). NMDA receptor antagonists including the high-affinity channel blocker MK-
801 block trigeminal nociceptive transmission (Storer & Goadsby, 1999). The obligate NR1 
subunit of NMDA receptors exists in the trigeminal nucleus caudalis (Bereiter & Bereiter, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
2000; Otahara et al., 2003) so NMDA channel agonists and blockers may act to modulate 
nociceptive neurotransmission at the second order synapse in this region. We therefore 
investigated the efficacy of Mg
2+
 and memantine to modulate trigeminovascular nociception 
in our rat model of trigeminovascular nociceptive activation, comparing direct application 
onto receptors in the trigeminal nucleus caudalis via microiontophoresis with systemic 
administration. 
 
Materials and Methods 
All protocols involving animals were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of California, San Francisco following the U.S. 
National Academy of Sciences Guide for the Care and Use of Laboratory Animals and in 
compliance with the U.S. Health Research Extension Act as specified by the U.S. National 
Institutes of Health. The molecular target nomenclature used conforms with the Guide to 
Receptors and Channels (Alexander et al., 2011). Male Sprague Dawley rats (n = 30) were 
used in the present study to reduce the effect of fluctuations in estrogen that can be avoided if 
male rats are used. If female rats are used we would need to ensure that they were at the same 
stage of their estrous cycle, which is impractical. This is because migraine (and therefore 
trigeminal excitability and activation) can be influenced by estrogen levels (Saleeon et al., 
2016), and in particular, to changes in these levels. In women, it is not the absolute level that 
triggers attacks, it is the sudden fall of estrogen levels (which triggers menstruation) that 
causes attacks (Chai et al. 2014). The rats were housed in a specific pathogen free facility in 
cages containing groups of rats on nesting material with at least one piece of environmental 
enrichment per cage (e.g., nestlet, shelter, or additional nesting material) and monitored for 
welfare considerations as specified by the Laboratory Animal Resource Center (LARC) of 
the University of California, San Francisco, under a 12 h light–dark cycle with free access to 
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standard laboratory food and sterilized water and acclimatized for at least a week before use. 
 
Surgical preparation of rats for electrophysiology 
A single dose of pentobarbital (60 mg/kg i.p., Nembutal, Lundbeck, Deerfield, IL) was used 
to induce anesthesia in previously untreated (drug naïve) male Sprague Dawley rats (300‒350 
g, Charles River Laboratories, Hollister, CA, USA) and propofol (20‒25 mg/kg per hour 
intravenously (i.v.); Propoflo, Abbott, Abbott Park, IL, USA) was used to maintain anesthesia 
throughout the experiments using systemic administration of test substances (n = 25 rats). For 
the longer term microiontophoretic experiments (n = 5 rats) anesthesia was maintained with 
intravenous infusions of -chloralose dissolved in 40% 2-hydroxypropyl--cyclodextrin 
(initial dose 60‒70 mg/kg, maintenance dose 10‒20 mg/kg per hour) (Storer et al., 1997). 
Left and right femoral veins were cannulated for administration of anesthetics and drugs. 
 
Physiological monitoring 
The left femoral artery was cannulated for continuous monitoring of arterial blood pressure 
using a transducer (DTX Plus DT-XX; Becton Dickinson, Sandy, UT, USA) connected to an 
amplifier (PM-1000; CWE, Ardmore, PA, USA). After a tracheostomy, the trachea was 
cannulated and the rats were ventilated (model 7025; Ugo Basile, Comerio, VA, Italy) with 
oxygen-enriched air (40% v:v, 1.0 L/min, 2.5‒3.5 mL per stroke, 80‒100 strokes per minute), 
and end-tidal CO2 was monitored (CapStar-100; CWE) and maintained between 3.5% and 
4.5%. The rats were placed on a heating blanket with a DC-power supply designed to emit 
only extremely low levels of electromagnetic-radiofrequency (EMF–RF) noise interference 
and thermostatically regulated by continuous feedback from a thermistor circuit 
(Homeothermic blanket system; Harvard Apparatus, Holliston, MA, USA) to maintain core 
body temperature at 37 ± 0.5 °C. The rat’s heads were fixed in a stereotaxic frame (Kopf 
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Instruments, Tujunga, CA, USA). Data regarding the variables described above, blood 
pressure, tidal CO2, and core temperature, was fed to a data acquisition system (Power 1401, 
CED, Cambridge, UK) and laptop computer where they were continuously displayed and 
monitored to assist maintenance between physiological limits, and stored on hard disk. 
 
Preparation for neuronal activity recording 
A dental burr was used under constant saline irrigation to create a craniectomy over the 
parietal cortex to expose the middle meningeal artery, its branches, and adjacent 
supratentorial dura mater (MMA). To avoid desiccation of the tissues, a thin layer of mineral 
oil was applied over the craniectomy. A bipolar electrode (NE200; Rhodes Medical 
Instruments, Summerland, CA, USA), connected to a stimulus isolation unit (SIU5A, Grass 
Instruments, West Warwick, RI, USA), was placed straddling the MMA with its poles 
touching the dura mater on either side. After separating the neck muscles, a C1 partial 
hemilaminectomy was performed to allow access to the cervical trigeminocervical complex 
(TCC). The spinal dura mater covering the area of the laminectomy was removed, and a 
tungsten electrode with a nominal impedance of 1.0 M (TM31A10; World Precision 
Instruments, Sarasota, FL) was introduced into the TCC for extracellular recording. For 
microiontophoretic experiments, a carbon-fiber recording electrode with an impedance of 1.0 
± 0.3 M when measured at 1 kHz in 0.9% saline (Impedance Check Module; FHC, 
Bowdoinham, ME, USA) tip size 19.5 ± 4.1 m, mean ± SD, incorporated into a 
multibarreled microiontophoretic pipette assembly (Carbostar-7S; Kation Scientific, 
Minneapolis, MN, USA), was used to record extracellular activity. To localize recording sites 
electrodes were advanced or retracted in 5 m steps using a piezoelectric motor-driven 
microelectrode positioner attached to a micromanipulator (model 1760-61; Kopf Instruments) 
while testing for receptive fields and poststimulus activity. Wide dynamic range (WDR) 
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neurons in the cervical trigeminocervical complex with convergent input from the MMA and 
cutaneous receptive fields were identified by noxious pinch and innocuous brush of the skin 
innervated by the first (ophthalmic) branch of the trigeminal nerve (V) and their response to 
electrical stimulation of the perivascular trigeminal afferents from the MMA and surrounding 
dura. 
 
Stimulation and recording of activity in the trigeminocervical complex 
Perivascular trigeminal afferents innervating the MMA and surrounding dura were stimulated 
using trains of 20 (experiments using systemic administration of test substances) or 25 
(microiontophoretic experiments) electrical square-wave pulses (8‒22 V for 0.1‒0.2 ms at 0.5 
Hz; S88 Stimulator, Grass Instruments, West Warwick, RI, USA) delivered through a bipolar 
NE200 stimulating electrode as described above. 
Signals from the recording electrodes were passed into a head-stage amplifier (NL100AK, 
Neurolog, Digitimer, Welwyn Garden City, Hertfordshire, UK) then passed to an AC 
preamplifier (NL104, Digitimer), set to a gain of 1000 or 2000 employing a low frequency 
cut-off filter at 10 Hz to remove DC components, before further band-pass filtering from 300 
Hz to 10 kHz using a filter module (NL125/126, Digitimer) without using the active 60 Hz 
notch filter to remove line frequency interference that was instead removed by passing the 
signal to a Hum Bug noise subtraction system (Quest Scientific, Vancouver, BC, Canada), 
which cancels 60 Hz line noise and its related harmonics up to 4 kHz without distortion of 
critical components or frequency characteristics of the desired signal that may be removed by 
notch filtering, before further amplification using an AC–DC amplifier (NL106, Digitimer) 
with a gain range of about 50‒100. From the AC–DC amplifier the signal was passed to a 
data acquisition system (Power 1401 with a Spike 2 expansion box; CED) and to a gated 
amplitude discriminator (NL201 Spike Trigger, Digitimer) the output of which was fed to the 
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data acquisition system to allow frequency logging, and to an oscilloscope and audio 
amplifier (NL120, Digitimer) to assist with spike discrimination by monitoring the direct 
output from the NL106 amplifier or spikes gated by the NL201. A storage oscilloscope 
triggered by the stimulus of the perivascular MMA afferents further assisted real-time spike 
discrimination by displaying activity from up to 100 ms post stimulation. All spike data 
where they were continuously displayed on a PC using Spike software (version 5; CED), and 
stored on hard disk as poststimulus histograms and as continuously monitored activity. 
 
Test substance administration 
Multibarreled microiontophoretic application 
On the day of the experiments, test substances for microiontophoresis were dissolved in water 
for injection (USP) and filtered to 0.02 m. Memantine hydrochloride (Tocris Bioscience) 
100 mM, pH 5.0; MgCl (Fisher Scientific) 100 mM, pH 5.0; monosodium L-glutamate (200 
mM, pH 8.0) and N-methyl-D-aspartate (NMDA 100 mM, pH 8.5) were both from Sigma-
Aldrich; pH of solutions was adjusted by adding solid sodium bicarbonate. Sodium chloride 
at neutral pH was used in a current control barrel (100 mM) and a current balance barrel (200 
mM). After filling, microiontophoretic pipette barrels passing useful (>10 nA) iontophoretic 
currents at ±135 V compliance usually had impedances of 5–20 M tested at 10 nA peak-to-
peak at 1 kHz in saline (Impedance Check Module; FHC) and resistances of 20–200 M in 
situ (6400A; Dagan, Minneapolis, MN, USA). 
A microiontophoresis current generator (6400A; Dagan) provided the currents for ejecting 
substances from the micropipette barrels and output current levels were passed to the data 
acquisition system (Power 1401 with a Spike 2 expansion box; CED) where it was collected 
and displayed simultaneously with free running spike activity using Spike 2 software (version 
5; CED, Cambridge, UK). L-Glutamate and NMDA were ejected as anions and retained with 
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small positive currents (approximately 3–5 nA) to restrain passive diffusion from barrels 
between ejection periods. If a neuron was responsive to L-glutamate and NMDA, the tip of 
the microiontophoretic pipette assembly was assumed to be close to a neuronal soma that has 
accessible glutamate receptors (and therefore second order synapse), and the ejection current 
required to produce a stable baseline response across at least 5 epochs of L-glutamate 
application or NMDA application, as demanded for cell testing, was established empirically 
for each neuron such that the firing activity of neurons was at a maximum of 30–200 Hz 
during pulses of application to avoid excitotoxicity. This current ranged from –10 to –60 nA. 
The current pulses were typically applied for 10 s and alternated with a similar or longer 
period of retention, so that inhibition, or facilitation, of neuronal firing by the test substances, 
could be determined and distinguished from random firing and noise without overexciting the 
neurons. Responses were quantified in continuous rate histograms using 1 s bins or using 0–
50 ms poststimulus histograms. Ejection currents for memantine, magnesium, and Na
+
 
control (with a Cl
–
 balancing current) were positive, ejecting these substances as cations in 
the range of from 5 to 80 nA, and small retaining currents of approximately –3 to –5 nA were 
used. Controls were based on passing currents of the same magnitude and direction through 
the barrel containing 100 mM NaCl. Active current balancing was always provided through 
the barrel containing 200 mM NaCl. 
 
Poststimulus histograms 
Baseline histograms of activity after stimulating perivascular trigeminal afferents innervating 
the MMA and surrounding dura were obtained by calculating the mean of three consecutive 
poststimulus histograms, each consisting of 20 stimuli (25 in microiontophoretic 
experiments) before any test substance or vehicle administration. The poststimulus 
histograms were collected immediately before, during, and after (to assess recovery for up to 
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1 h) microiontophoretically delivered substance interventions, which at the “during” phase 
had produced a steady state of inhibition at their highest dose. Nerve firing activity from the 
WDR neurons in the cervical trigeminocervical complex with convergent input from the 
perivascular MMA afferents and cutaneous receptive fields innervated by the ophthalmic 
division of trigeminal nerve were similarly collected while mechanically stimulating 
cutaneous receptive fields as described earlier. In practice about 5‒6 epochs of excitatory 
amino acid ejections equivalent to about 5 min of test substance ejection at the highest dose 
were made before poststimulus histogram collections during interventions and neuronal 
activity had recovered to baseline levels within 15 min of ceasing the microiontophoretic 
ejection currents and applying the described small retaining currents. 
 
Microiontophoretic study design 
For microiontophoretic experiments data were collected from up to several neurons, 
identified as described, in each previously untreated rat (n = 5 rats). We aimed to collect data 
from at least 5 and up to 7 neurons for each iontophoretic current used and for each substance 
tested. Glutamate and NMDA were applied in approximately 10 s pulses as described and 
then simultaneously, the iontophoretic currents for Mg
2+
, memantine, and Na
+
 (as proxies for 
doses based on Faraday’s Law, and as current controls in the case of Na+) were applied in a 
cumulative-dose fashion of at least 3 and up to 4 doses until a steady-state dose–response 
effect was seen at each dose (for at least 5 pulses of the excitatory amino acid) before 
allowing up to 1 h for recovery to pretest levels. The activity from 5 epochs of glutamate or 
NMDA application was averaged for each data point. The order of application of Mg
2+
, 
memantine, and Na
+
 was alternated to avoid ordering effects. The resource equation method 
(http://www.3rs-reduction.co.uk/html/6__power_and_sample_size.html) indicates an E of 
between 12 and 25 for these conditions, which should be adequate to detect substantial 
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effects with a low probability of a Type II error. 
 
Recording site localization 
At the end of the microiontophoretic protocols, the ends of electrode tracks were marked with 
electrothermolytic lesions (anodal DC current of 25 A for 20–30 s; Model DC-LM5 lesion 
maker, Grass Instruments). The traditional Chicago Sky Blue marking method was not used, 
allowing an additional barrel to be used for test substances providing direct within cell 
comparisons of responses to test substances and controls. At the end of experiments rats were 
humanely killed with an overdose of sodium pentobarbital (Nembutal, Hospira, Lake Forest, 
IL; 80 mg/kg i.p.). The lesioned spinal cord tissue was excised by dissection, fixed in neutral 
buffered 10% formalin (4% formaldehyde), cryoprotected with 30% sucrose (w/v) in 
phosphate buffered saline at 4 °C until saturated, embedded in optimal cutting temperature 
medium for frozen tissue specimens (OCT, Sakura Finetek, Torrance, CA) on a cryostat 
freezing chuck, sectioned in a coronal plane perpendicular to the imaginary horizontal plane 
joining Bregma and lambda at 40 m intervals on a cryostat (CM3050 S; Leica 
Microsystems, Nussloch, Germany) at –16 to –25 °C, and serial sections mounted on gelatin-
coated glass slides. The lesion marks were visualized using a Zeiss Axioplan Universal 
microscope (Carl Zeiss Microscopy). Images were processed using AxioVision LE software 
(version 4.6, Carl Zeiss MicroImaging) and recording positions relative to the lesion marks 
and cord surface determined using digital caliper software and from digital positioning output 
from the microelectrode positioner and stereotaxic measurements from the midline of the 
cord and the obex. In this manner, the recording positions were reconstructed and projected 
onto a schematic representation of the cord at C2 (Molander & Grant (1995). 
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Systemic test substance administration and study design 
After acquiring three baseline poststimulus histograms (15, 10 and 5 min before intravenous 
infusion of test substances or vehicle control), memantine (10 mg/kg in water for injection 
USP) or magnesium sulphate (Fisher Scientific, Pittsburg, PA; 100 mg/kg in water for 
injection USP) were administered intravenously. The volume administered was 1 mL. As a 
positive control, naratriptan (Sigma-Aldrich, St. Louis, MO; 5 mg/kg in water for injection 
USP)(Cumberbatch et al., 1998), or the vehicle control were administered. Poststimulus 
histograms were acquired before and at 5, 10, 15, 20, 25, 30 and 45 min after administering 
test substances or controls. We allocated 6 previously untreated rats to each of MgSO4, 
memantine, and the vehicle control treatments, and 7 rats for the positive naratriptan control 
treatment in an unselected manner. The resource equation method indicates an adequate E of 
21 for these conditions, albeit to detect substantial effects. 
 
Statistical analyses 
Statistical analyses were performed using IBM SPSS Statistics for Windows (version 19.0, 
IBM Corporation, Armonk, NY). Data are expressed as mean values with standard errors of 
the mean (SEM) unless otherwise specified. Treatment effects within one group were 
analyzed using an ANOVA with repeated measures. If the assumption of sphericity was 
violated Greenhouse–Geisser corrections were applied. Bonferroni or Dunnett post hoc tests 
were applied for multiple comparisons. Two-sided unpaired Student t tests were used to 
compare poststimulus histograms with pretreatment baseline values. P < 0.05 was considered 
significant in tests of inference. The results are expressed as percentages of baseline. 
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Results 
Microiontophoretic administration of low-affinity NMDA-receptor channel blockers 
significantly inhibits NMDA-, glutamate-, craniovascular afferent-, and receptive field-
evoked trigeminal neuron firing 
All neurons tested in microiontophoretic experiments were classified as wide-dynamic range 
neurons and had facial cutaneous receptive fields, primarily restricted to the territory of the 
first (ophthalmic or V1) division of the trigeminal nerve (n = 11 neurons), including the 
cornea, although some overlap with the second (maxillary or V2) trigeminal division was 
sometimes observed. Microiontophoretic application of magnesium and memantine at the 
second-order synapse of trigeminocervical neurons in the trigeminovascular system linked to 
MMA-stimulation and convergent V1 input from receptive fields (Fig. 1) inhibited the 
neuronal response to L-glutamate (Fig. 2A) and NMDA (Fig. 2B) applied 
microiontophoretically in the same region, in a reversible, dose-dependent manner. The 
inhibition was significant even at low currents after NMDA-evoked firing compared with 
current-matched sodium chloride controls. By contrast, although the inhibition of L-
glutamate-evoked firing was significant, the inhibition was usually less than the inhibition of 
NMDA-evoked firing and not complete, even at the highest currents used. Neuronal firing 
was inhibited more profoundly by memantine than by magnesium (Fig. 2A–C) and activity 
inhibited by memantine recovered more slowly (Fig. 2C). Current-matched sodium controls 
(with an equivalent chloride balance current) did not affect firing significantly, although an 
increased tendency was noted at the highest current (80 nA) used. 
Magnesium and memantine delivered microiontophoretically to the second-order synapse of 
trigeminocervical neurons in the trigeminovascular system (Fig. 1) also inhibited the neuronal 
response to V1 cutaneous receptive field mechanostimulation (Fig. 3A) and electrical 
stimulation of afferents from the MMA and perivascular dura (Fig. 3B). Current-matched 
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sodium chloride controls did not significantly inhibit the responses evoked by 
mechanostimulation of cutaneous receptive fields or electrical stimulation of afferents from 
the MMA and perivascular dura. Representative poststimulus histograms show reversible 
inhibition by memantine and Mg
2+
, but not sodium chloride, of neuronal firing evoked by 
electrical stimulation of afferents from the MMA and perivascular dura (Fig. 3C). 
 
Intravenous systemic administration of moderate concentrations of low-affinity NMDA-
receptor channel blockers does not inhibit stimulus-evoked firing significantly 
Systemic administration of magnesium at 100 mg/kg intravenously did not significantly 
inhibit stimulus-evoked neuronal firing in the trigeminocervical complex (F2.5, 12.37 = 1.72, P 
= 0.217, n = 6; ANOVA followed by a Bonferroni post hoc test). Similarly, memantine 
administered at 10 mg/kg intravenously failed to inhibit neuronal firing in the 
trigeminocervical complex significantly (F2.2, 11.2 = 0.70, P = 0.531, n = 6). By contrast, 
naratriptan at 5 mg/kg intravenously, which was used as a positive control, was strongly 
inhibitory (F3.3, 19.9 = 33.43, P < 0.001, n = 7), with inhibition reaching a maximum 30 
minutes after intravenous administration (61 ± 6%, t6 = 11.00, P < 0.001). Vehicle control 
administered intravenously had no significant effect on the neuronal firing (F2.5, 12.4 = 0.98, P 
= 0.419, n = 6) (Fig. 5). As can be seen from Figures 4B and 4C the effect of memantine 
appears to have a bimodal distribution, with some animals responding to about 30% 
inhibition at 5 min with others showing no effect (nonresponders) or even excitation. By 30 
min the effect of Mg
2+
 is reducing, while the effect of naratriptan increases, the effect of 
memantine is about the same, perhaps slightly increased in the animals that responded. 
Compared with vehicle controls, magnesium and memantine exerted strong, but short lasting, 
reductions in arterial blood pressure. The maximum reduction was 49 ± 11% (t5 = 4.54, P = 
0.006) after administering magnesium and 31 ± 5% (t5 = 6.31, P = 0.001) after memantine. 
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Blood pressure returned to pretreatment levels in both groups within 5 min. Naratriptan 
induced a weaker, but longer lasting reduction in blood pressure (26 ± 5%, t6 = 5.35, P = 
0.002) that did not return to pretreatment levels within 45 min. 
 
Discussion 
In the present study, we demonstrate that the microiontophoretic delivery of the low-affinity 
NMDA-receptor channel blockers magnesium and memantine into the trigeminocervical 
complex inhibit L-glutamate- and NMDA-evoked responses from trigeminocervical complex 
neurons at the second order trigeminal synapse linked to afferents from the MMA and its 
perivascular dura and cutaneous receptive fields in a rat model of trigeminal nociception. 
Moreover, microiontophoretic delivery of magnesium and memantine also inhibited 
nociceptive responses from the same trigeminocervical complex neurons following electrical 
stimulation of afferents from the MMA and its perivascular dura and mechanostimulation of 
cutaneous afferents. However, when magnesium and memantine were delivered systemically 
at moderate concentrations these nociceptive responses were not significantly inhibited. 
Higher concentrations of magnesium and memantine may be necessary to obtain significant 
inhibition. 
Glutamate, well known as the most important and abundant excitatory neurotransmitter in the 
CNS, is likely to be fundamental to the pathophysiology of migraine (Ramadan et al., 2003; 
Vikelis & Mitsikostas, 2007). NMDA receptor channel blockers, which effectively impede 
the influx of Ca
2+
 and thereby channel function, differentiate among each other in their 
affinity for the receptor, their blocking and unblocking kinetics, and consequently in their 
voltage-dependency. A lower receptor affinity leads to faster blocking and unblocking 
kinetics, and a higher voltage-dependency. Substances with these lower NMDA receptor 
affinity properties, such as magnesium and memantine are characterized by fewer and less 
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severe side effects than substances with slower receptor kinetics, and are therefore widely 
used for several clinical conditions. Substances with slow receptor kinetics such as ketamine, 
phencyclidine, and dizolcipine (MK-801) induce clinically unacceptable side effects, such 
that their use is limited to certain conditions and routes of administration impede their use on 
an outpatient basis (ketamine) or even at all (dizolcipine) (Chizh, 2007). Magnesium and 
memantine show only very limited side effects compared with current preventive treatment 
options. Magnesium represents one of the very few preventives that can be used during most 
trimesters of pregnancy. 
That several NMDA receptor channel blockers suppress CSD in the rat (Lauritzen & Hansen, 
1992; van der Hel et al., 1998; Peeters et al., 2007) supports the hypothesis that glutamate is 
fundamental to the pathophysiology of migraine. Consistent with these findings, magnesium 
deficiency increases the sensitivity of NMDA receptors to glutamate-induced CSD (Van 
Harreveld & Fifkova, 1973). Memantine significantly reduces nociceptive behavioral 
responses and c-Fos expression in the trigeminocervical complex induced by the injection of 
formalin into the periorbital area of rats (Park et al., 2012). Experiments from our laboratory 
in cats have demonstrated that intravenous administration of the NMDA-receptor channel 
blocker dizocilpine is able to inhibit neuronal firing (Storer & Goadsby, 1999) and c-Fos 
expression in the trigeminocervical complex evoked by electrical stimulation of 
craniovascular and perivascular dural afferents (Classey et al., 2001). These findings strongly 
suggest a glutamatergic mechanism for trigeminal nociception and the potential of NMDA 
receptor channels as therapeutic targets for migraine. 
Clinical studies of migraineurs support the evidence obtained from laboratory research. By 
analogy with the findings from in vivo experiments showing that NMDA receptor channel 
blockers are able to inhibit CSD, intranasally administered ketamine is able to attenuate 
migraine aura (Kaube et al., 2000; Afridi et al., 2013). Results from a small clinical trial 
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suggest that subcutaneously administered ketamine is useful for the treatment of migraine 
pain (Nicolodi & Sicutieri, 1995). 
Low magnesium levels have been found in serum, saliva, and CSF of migraineurs (Jain et al., 
1985; Sarchielli et al., 1992). The noninvasive measurement of brain magnesium by NMR 
spectroscopy showed reduced levels in migraineurs (Ramadan et al., 1989). Measurements of 
ionized magnesium in serum also showed reduced levels in migraineurs (Mauskop et al., 
1995; 1996). Subsequently, clinical studies were conducted to elucidate the potential efficacy 
of the low-affinity NMDA-receptor channel blockers magnesium and memantine for 
migraine treatment. Many of these studies had several shortcomings including small sample 
sizes, retrospective design, or lack of separation between different types of primary 
headaches. Nevertheless, these studies showed promising results (Mauskop et al., 1995; 
1996; Charles et al., 2007; Bigal et al., 2008), including a positive randomized placebo-
controlled trial (Noruzzadeh et al., 2016). However, the promising results for magnesium 
could not always be satisfactorily reproduced in the randomized controlled trials (Peikert et 
al., 1996; Pfaffenrath et al., 1996; Bigal et al., 2002). To our knowledge, randomized 
controlled trials analyzing the efficacy of memantine for migraine treatment have not yet 
been reported. 
Local administration of magnesium and memantine into the trigeminocervical complex 
inhibits trigeminal nociceptive responses in the trigeminocervical complex, perhaps through a 
sufficiently high concentration at the NMDA receptors to block transmission of nociception 
there. However, using intravenous administration, which provides a systemic dose, more 
closely resembling administration in humans, we failed to find significantly reduce neuronal 
responses in the trigeminocervical complex to electrical craniovascular and meningeal 
stimulation at moderate, and perhaps clinically achievable concentrations. This finding may 
provide an explanation for the contradictory results of randomized controlled trials with 
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magnesium. A lower concentration at the sites of action within the CNS after systemic 
administration might account for the lack of clinically significant effects. However, the doses 
used in this study are high compared with those used in humans, where the usual magnesium 
dosage used in the clinical trials for the prophylactic treatment of migraine was 1000 mg per 
day (Mauskop et al., 1995; 1996), and that for memantine is 10–20 mg per day for treatment 
of Alzheimer’s disease. Even considering the difficulty in comparing dosages used in humans 
to those used in animals during experiments in vivo, a further increase in dose was not 
practical in the experiments performed, because the intravenous doses used for both 
magnesium and memantine already induced significant decreases in blood pressure that 
might affect firing rate of trigeminal nociceptive neurons or even result in cerebral 
hypoperfusion, albeit temporarily. A change of structure that leads to different unblocking 
kinetics for the channel blocker might provide a solution to this problem, by providing 
blocking sufficiently high enough to block nociception, but not so strong as to produce 
unwanted side effects impeding its clinical use. 
The present study is limited in that we did not specifically identify neurons in the 
trigeminocervical complex with dural input in the immunohistochemical study. Identification 
of neurons with dural input would require further experiments such as might be conducted 
using retrograde tracers such as DiI applied to the perivascular dura (Fioretti et al., 2011). 
The retrograde tracing might be combined with further confirmatory localization such as in 
situ hybridization and further immunochemical controls, such as the use of other primary 
antibodies directed against a different epitope, and more precise confocal laser scanning 
microscopy. 
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Although the concept of dose in microiontophoretic experiments essentially follows 
Faraday’s Law, for various reasons it is difficult to control the dose of substance delivered to 
the neuron and each experimental circumstance may differ slightly (Stone, 1985). It is 
possible that magnesium and memantine were acting nonspecifically at high local 
concentrations and that including AMPA as a control might have improved interpretation. 
Aside from technical limitations on the number of agonists and antagonists that can be used 
in the experiments, the specificity of magnesium as a channel blocker is well known. Herero 
et al. (1994) had already determined that memantine is relatively specific for NMDA 
receptors so we wanted to determine the overall effect of memantine and magnesium on 
glutamatergic transmission to estimate the contribution of NMDA receptor channels on 
glutamatergic transmission overall. Both substances are not particularly potent with 
memantine being about 6 times weaker than ketamine (Herero et al., 1994). We were able to 
see effects at relatively low currents being significant at 5–20 nA in the case of memantine. 
That NMDA and glutamate evoked activity was similarly inhibited, although glutamate to a 
lesser extent suggests that NMDA receptors make a substantial contribution to the overall 
glutamatergic transmission, which may explain the relative lack of clinical effectiveness of 
AMPA receptor antagonists such as BGG492 (Gomez-Mancilla et al., 2014). In the 
microiontophoretic experiments we recorded from 11 neurons in 5 rats. An advantage of 
microiontophoresis is of being able to record more than one unit in a single rat reducing the 
number of animals required. Moreover, the multibarreled technique and fast diffusion of 
substances from the area of local application allows for the testing of multiple substances on 
a single neuron. 
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For technical reasons involving blood pressure and solubility we did not use the higher doses 
of memantine of up to 32 mg/kg that have been used by others (Herrero et al., 1994). The 
means that we may have missed seeing a significant effect of memantine that might have 
been seen at a higher concentration. The effect of memantine appears to be distributed 
bimodally, with some animals responding while others are nonresponders. For the animals 
that did respond, the effect of memantine was greater than for Mg
2+
, at least at 30 min, which 
is what is expected and consistent with the iontophoretic data. It would be useful to review 
the data presented in the clinical studies (Cammarata & Krusz, 2005; Kew & Kemp, 2005; 
Charles et al., 2007; Bigal et al., 2008; Spengos et al., 2008; Noruzzadeh et al., 2016) to see if 
there are groups of responders and nonresponders. 
 
Conclusion 
To our knowledge, this is the first study that compares the effectiveness of the low affinity 
NMDA-receptor channel blockers memantine and magnesium on central trigeminal 
nociceptive transmission and demonstrates poor effectiveness in their more clinically relevant 
systemic administration providing a potential explanation for their uncertain effect in the 
treatment of migraine and primary head pain. Nevertheless, the present results suggest 
blocking NMDA-receptor channels is an effective way to inhibit nociceptive activation in the 
trigeminocervical complex. Further exploration of such channel blockers as a therapeutic 
strategy for primary head pain is warranted. 
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Figure 1. Sites of neurons (n = 11) recorded in the trigeminal nucleus caudalis/cervicalis 
(trigeminocervical complex) at the level of C1, reconstructed from marks made at the end of 
electrode tracts using electrothermolytic lesions. Figure 1 shows the recording sites for the 
microiontophoresis experiments on the same neurons using different stimuli, as shown in 
Figure 2 (excitatory amino acid (microelectrophoretic delivery) stimulated activity) and 
Figure 3 (V1 cutaneous receptive field mechanostimulation (Figure 3A) and stimulation of 
afferents from the middle meningeal artery or its branches and periarterial dura mater (MMA) 
(Figure 3B) with microiontophoretic delivery of memantine and Mg
2+
 at various currents in 
Figure 2 and at maximal currents in Figure 3. The timing of MMA stimulus is seen in Figure 
2C. The cord representation is based on a figure by Molander and Grant (Molander & Grant, 
1995) with permission. 
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Figure 2. Scatter plots showing that microiontophoretic application of magnesium and 
memantine (5–80 nA) inhibited the response of trigeminovascular neurons to L-glutamate (n 
= 9 neurons for memantine, and 7 neurons for Mg
2+
, panel A) and NMDA (n = 5 neurons for 
memantine, and 7 neurons for Mg
2+
, panel B) in a reversible, dose-dependent manner, with 
inhibition of NMDA-evoked activity by memantine reaching significance even at the lowest 
current used (5 nA, t = 6.23, P < 0.001) compared with current-matched sodium controls. 
Memantine and Mg
2+
 were applied to the same neurons in alternating order with NMDA and 
L-glutamate in alternating order to avoid ordering effects. However, because of technical 
difficulties including channel blocking and electrode drift, not all neurons provided data for 
all substances. The inhibition of L-glutamate-evoked activity was significant, but usually 
partial that of NMDA, even at the highest currents used (20 nA memantine, t = 6.83, P < 
0.01; 80 nA Mg
2+
, t = 3.73, P < 0.05). *P < 0.05, **P < 0.01, ***P < 0.001, 
###
P < 0.001. 
The bars indicate means. Asterisks (*) indicate comparisons with sodium current controls 
(Dunnett’s t). Hash marks (#) indicate comparisons with recovery of activity from inhibition. 
R indicates recovery from inhibition during which time memantine, Mg
2+
, and Na
+
 were 
retained in the barrels of the microiontophoretic electrode. (C) Representative inhibition of 
NMDA-evoked firing shown as free-running activity in a histogram with 1 s bins. Neuronal 
firing was more profoundly inhibited by memantine and activity recovered more slowly than 
with magnesium. MMA (bars) represent electrical stimulation of afferents from the middle 
meningeal artery or its branches and periarterial dura mater. Sodium current matched controls 
(with an equivalent chloride balance current) did not significantly affect firing, although 
sodium’s tendency to inhibit was noted at the highest current used. 
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Figure 3. Memantine and magnesium reversibly inhibited the response of trigeminovascular 
neurons to (A) V1 cutaneous receptive field mechanostimulation (n = 5 neurons, F2,10 = 27.5, 
P < 0.001) and (B) stimulation of afferents from the middle meningeal artery or its branches 
and periarterial dura mater (MMA), whereas no significant inhibition, shown as percentage 
change, was observed with current-matched sodium (chloride) controls (n = 6 neurons for 
memantine, t9 = 5.15, P < 0.001; 5 neurons for Mg
2+
, t9 = 2.93, P < 0.05; 5 for Na
+
), *P < 
0.05, ***P < 0.001. The bars indicate means. (C) Representative poststimulus histograms 
showing reversible inhibition by memantine and Mg
2+
, but not sodium chloride, of neuronal 
firing evoked by electrical stimulation of afferents from the MMA and perivascular dura. The 
stimulus artifact is seen on the far left of each histogram. Sites of neurons (n = 11) recorded 
in the trigeminal nucleus caudalis/cervicalis are seen in Figure 1. 
 
Figure 4. Effect of intravenous administration of magnesium (100 mg/kg), memantine (10 
mg/kg), and naratriptan (5 mg/kg) on inhibition of neuronal firing in the trigeminocervical 
complex evoked by electrical stimulation of afferents from the MMA and perivascular dura. 
(A) Time course in minutes with baseline firing measured at 5, 10, and 15 min before 
systemic administration of test substances and controls at time 0 min. The group means are 
displayed as lines and shaded regions represent standard errors above and below the means. 
(B) Difference plot (from 0) of individual data at 5 min. (C) Difference plot (from 0) of 
individual data at 30 min. Bars show median values. Drawn using the interactive line graph 
tool available at http://statistika.mfub.bg.ac.rs/interactive-linegraph/ as described by 
Weissgerber et al. (2016). 
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